U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07321301) titled 'Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia' on Dec. 22, 2025.
Brief Summary: The purpose of this study is to determine the efficacy and safety of the CAR-T cell immunotherapy utilizing polymer-lipid nanoparticles for delivering CD19/CD20 dual-targeting InViVoCAR1920 mRNA, for the first-line consolidation therapy of relapsed/refractory B-cell lymphoma/leukemia.
Study Start Date: Sept. 01, 2025
Study Type: INTERVENTIONAL
Condition:
B-cell Lymphoma Refractory
Intervention:
DRUG: Polymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoCAR1920 m...